AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Xeris Biopharma Holdings, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG012V1MG61
10.20▼ 0.66 (-6.08%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
10.86
Day's Range
10.06 – 10.85
52-Week Range
5.25 – 11.42
Volume
2.4M
Avg Volume
2.9M
Share Statistics
Shares Outstanding
Employees
435
Exchange
XNAS
Listed
2018-06-21
Share count as of July 31, 2026

Xeris Biopharma Holdings, Inc. Common Stock (XERS) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Xeris Biopharma Holdings, Inc. Common Stock (XERS)
What is Xeris Biopharma Holdings, Inc. Common Stock's Market Cap?
Xeris Biopharma Holdings, Inc. Common Stock's Market Cap is $1.9B, based on as-reported figures from SEC (XBRL) filings.
What is Xeris Biopharma Holdings, Inc. Common Stock's Enterprise Value?
Xeris Biopharma Holdings, Inc. Common Stock's Enterprise Value is $2.0B, based on as-reported figures from SEC (XBRL) filings.
What is Xeris Biopharma Holdings, Inc. Common Stock's Price / Sales?
Xeris Biopharma Holdings, Inc. Common Stock's Price / Sales is 5.5×, based on as-reported figures from SEC (XBRL) filings.
What is Xeris Biopharma Holdings, Inc. Common Stock's EV / Revenue?
Xeris Biopharma Holdings, Inc. Common Stock's EV / Revenue is 5.9×, based on as-reported figures from SEC (XBRL) filings.
What is Xeris Biopharma Holdings, Inc. Common Stock's EV / EBITDA?
Xeris Biopharma Holdings, Inc. Common Stock's EV / EBITDA is 55.7×, based on as-reported figures from SEC (XBRL) filings.
What is Xeris Biopharma Holdings, Inc. Common Stock's Revenue (TTM)?
Xeris Biopharma Holdings, Inc. Common Stock's Revenue (TTM) is $335.4M, based on as-reported figures from SEC (XBRL) filings.
What is Xeris Biopharma Holdings, Inc. Common Stock's Net Income (TTM)?
Xeris Biopharma Holdings, Inc. Common Stock's Net Income (TTM) is -$17.2M, based on as-reported figures from SEC (XBRL) filings.
What is Xeris Biopharma Holdings, Inc. Common Stock's EBITDA?
Xeris Biopharma Holdings, Inc. Common Stock's EBITDA is $37.9M, based on as-reported figures from SEC (XBRL) filings.
What is Xeris Biopharma Holdings, Inc. Common Stock's Diluted EPS (TTM)?
Xeris Biopharma Holdings, Inc. Common Stock's Diluted EPS (TTM) is -0.09, based on as-reported figures from SEC (XBRL) filings.
What is Xeris Biopharma Holdings, Inc. Common Stock's EBITDA Margin?
Xeris Biopharma Holdings, Inc. Common Stock's EBITDA Margin is 11.3%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · XERSAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Product revenue, net
YoY growth+28.7%+38.3%+42.8%+37.1%
Costs and expenses:
Cost of goods sold
Research and development
Selling, general and administrative
Amortization of intangible assets
Total costs and expenses
Income from operations
% of revenue5.6%9.5%19.5%9.0%
Other income (expense):
Interest and other income
Loss on debt extinguishment, net———
Interest expense
Total other expense
Net loss before income taxes
Net loss
% of revenue-33.8%2.7%12.9%0.8%
Net loss per common share - basic (in dollars per share)
Net loss per common share - Diluted (in dollars per share)